{"groups":[{"description":"Participants received 1.8 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG000","title":"Dose 1"},{"description":"Participants received 3.6 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG001","title":"Dose 2"},{"description":"Participants received 7.2 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG002","title":"Dose 3"},{"description":"Participants received 12 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG003","title":"Dose 4"},{"description":"Participants received 18 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG004","title":"Dose 5"},{"description":"Participants received 27 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG005","title":"Dose 6"},{"description":"Participants received 40 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG006","title":"Dose 7"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG007","title":"Dose 8"},{"description":"Participants received 80 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG008","title":"Dose 9"},{"description":"Participants received 60 mg/m\\^2 of KZR-261. Participants received 3 doses in a 28-day cycle as an intravenous (IV) infusion for up to six cycles.","id":"FG009","title":"Melanoma Expansion Cohort"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"17"},{"groupId":"FG008","numSubjects":"8"},{"groupId":"FG009","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"5"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"17"},{"groupId":"FG008","numSubjects":"8"},{"groupId":"FG009","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"At the time of study termination, Part 2A of the study had only enrolled participants with melanomas. Part 2B of the study (Dose Optimization) did not occur."}